Abstract 12462: Improved Treatment Satisfaction Independent of Stroke and Bleeding Risk Among Patients Transitioned From a Vitamin K Antagonist to Rivaroxaban: A XANTUS-ACTS Analysis
Bibliographic record
Abstract
Introduction: The effectiveness, safety and ease of use of rivaroxaban may reduce anticoagulation treatment burden and improve nonvalvular atrial fibrillation (NVAF) patient satisfaction compared to vitamin K antagonists (VKAs). Objective: To assess consistency in changes in treatment satisfaction among patients transitioned from a VKA to rivaroxaban in routine practice across stroke and bleeding risk subgroups. Methods: Xarelto on Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation (XANTUS) was a prospective, non-interventional study in patients prescribed rivaroxaban for prevention of stroke in routine practice within 7 European countries and Canada. Patients receiving a VKA 4-weeks prior to the initial XANTUS study visit and switched to rivaroxaban were asked to complete the Anti-Clot Treatment Scale (ACTS). Changes in scores, as recorded during the initial and first follow-up visit at ~3-months (corresponding to a comparison of rivaroxaban vs. prior VKA) for the ACTS Burdens and Benefits scores, were calculated and reported as least squares (LS)-mean differences with standard errors. Results: After ~3-months’ rivaroxaban treatment, both Burdens and Benefits scores were significantly improved in NVAF patients with prior VKA treatment ( Table ). Improvements in Burden scores across subgroups were generally consistent (LS-mean difference range, 2.68 to 3.46) with the overall cohort findings. The Benefit score improved in the overall cohort, but was not found to significantly differ in any subgroup (LS-mean difference range, -0.26 to 0.58). Conclusions: In XANTUS, patients switching from a VKA to rivaroxaban for stroke prevention reported significant improvements in treatment satisfaction. Independent of stroke or bleeding risk, switching to rivaroxaban appears to improve patient treatment satisfaction; mainly due to a perceived lower treatment burden
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.003 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.003 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".